NASDAQ:IMPL
Impel Pharmaceuticals Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
impelpharma.comipo date
Apr 23, 2021
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105,...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus